In an age of austerity, biobanks are increasing in number; the UK government alone committed a large sum of money – in the region of £250m - to develop future research initiatives and with leading pharmaceutical companies worldwide also continuing to invest in R&D, biobanks continue to prove pivotal for future drug discoveries.
Faced with fantastic commercial growth opportunities, issues are continuing to resonate within biobanking with international regulations, patient consent, quality of samples, and attracting investors, proving to be the key stumbling blocks. SMi's Biobanking conference tackles these issues with a fresh perspective: join our unique forum today to discover innovative research from leading pharma, understand the true logistics behind a successful biobank and develop partnerships to ensure you are implementing frameworks for a globalisation of biobanks.
Biobanking 2011 is SMi’s inaugural event, acting as a bridge between the worlds leading academia and pharma, this truly is a perfect opportunity to market with an extremely targeted delegate audience that will be making a huge difference in future drug discovery.
Key Note Speakers Include:
Benefits of Attending Include: